Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress

– Trial to be conducted at University of Washington, led by Dr. Anthony Back – TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics”, today announced that the U.S. Food and Drug Administration (“FDA”) has authorized an investigator-initiated randomized…

Source